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Abstract
Background: The aim of this study is to evaluate vitamin D levels in children with latent and active TB compared
to healthy controls of the same age and ethnical background.
Methods: A multicenter observational study has been conducted in three tertiary care paediatric centres: Anna
Meyer Children's University Hospital, Florence, Italy; Evelina London Children's Hospital, London, United Kingdom
and Great Ormond Street Hospital, London, United Kingdom. Vitamin D was considered deficient if the serum level
was <25 nmol/L, insufficient between 25 and 50 nmol/L and sufficient for a level >50 nmol/L.
Results: The study population included 996 children screened for TB, which have been tested for vitamin D. Forty-four
children (4.4%) had active TB, 138 (13.9%) latent TB and 814 (81.7%) were controls. Our study confirmed a high prevalence
of hypovitaminosis D in the study population. A multivariate analysis confirmed an increased risk of hypovitaminosis D in
children with latent and active TB compared to controls [(P = 0.018; RR = 1.61; 95% CI: 1.086-2.388), (P < 0.0001; RR = 4.587;
95% CI:1.190-9.608)].
Conclusions: Hypovitaminosis D was significantly associated with TB infection in our study. Further studies are needed to
evaluate a possible role of vitamin D in the treatment and prevention of tuberculosis in children.
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Background
In the pre-antibiotic era, cod liver oil and sunlight ex-
posure were used to treat tuberculosis (TB) [1,2]. More
recently, increasing evidences from in vitro studies sug-
gest that vitamin D enhances antimycobacterial immun-
ity [3]. Several authors reported hypovitaminosis D in
TB patients [4-6], and serum level of vitamin D [25-
hydroxycholecalciferol) was found to be lower in TB pa-
tients than in healthy controls [7-14]. A recent study
conducted among adult TB contacts found that 94% of
recruits were vitamin D insufficient and that a single,
oral 2.5 mg dose of vitamin D significantly enhanced
their anti-mycobacterial immunity in vitro [7]. Factors
such as low socioeconomic status, poor nutrition, trad-
itional/cultural traits, and little exposure to sunlight may
contribute to vitamin D deficiency [15].
Mechanisms through which vitamin D modulates the im-
mune system in the response to Mycobacterium tubercu-
losis infection are not completely understood, two possible
mechanisms have emerged as the most likely. Vitamin D
appears to reduce the viability of M. tuberculosis by enhan-
cing the fusion of the phagosome and lysosome in infected
macrophages [16]. In addition, vitamin D may enhance the
production of LL-37, an antimicrobial peptide of the cathe-
licidin family [16-19]. Antimicrobial peptides, such as
defensin and cathelicidin, are involved as a first line of de-
fences in the prevention of infections, including tubercu-
losis. The presence of vitamin D in neutrophils and
macrophages up-regulates in a dose-dependent manner the
hCAP-18 gene that codes for LL-37, which suggests that
vitamin D induction of LL-37 may play a role in host de-
fences against TB infection [3,16].
Vitamin D exerts its actions through vitamin D receptor
(VDR), a nuclear hormone receptor. Polymorphisms in
the VDR gene, which may influence VDR activity and sub-
sequent downstream vitamin D mediated effects, were
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therefore studied as potential candidates of risk markers
for various clinical outcomes [20,21].
Clinical trials [8,10,22-24] have been conducted to test
whether vitamin D therapy improves TB outcomes, sug-
gesting that vitamin D may be beneficial as an adjunctive
treatment to the traditional therapy in patients with TB;
however, additional trials in children need to be conducted
to clarify its role [25].
Methods
A multicenter study was conducted in three tertiary care
paediatric centres: Anna Meyer Children's University Hos-
pital, Florence, Italy; Evelina London Children's Hospital,
London, United Kingdom and Great Ormond Street Hos-
pital, London, United Kingdom. The data regarding the
period of time between July 2008 and January 2013 were
collected retrospectively, whereas those between February
and September 2013 prospectively. Written informed con-
sent for participation in the study was obtained from chil-
dren's parent or guardian. The aim of the study was to
evaluate vitamin D levels in children with latent and active
tuberculosis, compared to healthy controls of the same age
and ethnical background. Secondary objective was to evalu-
ate potential differences between groups of patients (consid-
ering age, race, enrolling centre, vitamin D supplementation,
latent or active tuberculosis).
Study design
Children (aged <18 years) investigated for TB infection
between July 2008 and September 2013, for whom vita-
min D was tested during the first visit, were eligible.
The reasons for referral to the paediatric infectious dis-
eases centres were clinical suspicious or confirmed TB
disease, history of TB contact or immigrated/adopted
child from a TB endemic country within the previous
2 years. Children with congenital or acquired immuno-
deficiency were excluded.
For each child the following data were entered into
the study database: name, age, gender, ethnic group, fa-
milial and personal history including risk factors for TB
infection and for vitamin D deficiency, bacillus Camette-
Guerin (BCG) vaccination and physical examination.
Data about tests performed were also included, in par-
ticular vitamin D level (25-hydroxycholecalciferol, 25-
OHD), tuberculin skin test (TST), interferon-γ release
assay (IGRA), and if available calcium, phosphate, chest
x-ray, chest computerised tomography, gastric aspirate
or sputum (microscopy, culture and polymerase chain
reaction for M. tuberculosis) and anti-tubercular treat-
ment. All results were recorded in the study database
following the international standards for the protection
of privacy and personal information.
Ethical issues
This study was approved by the Ethical Committees of
the hospitals involved: Anna Meyer Children's University
Hospital, Florence, Italy; Evelina London Children's Hos-
pital, London, United Kingdom and Great Ormond
Street Hospital, London, United Kingdom.
Case definitions
TB disease
Active TB diagnosis was assigned to any child with Myco-
bacterium tuberculosis cultured or detected by microscopy
or molecular methods from sputum, gastric aspirate or
other biologic samples. Active TB diagnosis was also
assigned to any child with clinical and radiological evi-
dence of TB disease, and with either a history of exposure
to an infectious case or a positive TST. In the absence of a
recognized gold standard, latent tuberculosis diagnosis
was assigned to any child with a positive TST and/or
IGRA and no clinical, bacteriological or radiographic evi-
dence of active TB [26]. In the absence of those criteria
children were included in the control group.
Hypovitaminosis D
Vitamin D level was evaluated testing for 25-OHD, which
is considered its best indicator [27]. Following the European
Society for Paediatric Gastroenterology, Hepatology and
Nutrition (ESPGHAN) definition, 25-OHD was considered
deficient in case of a serum vitamin D level less than
25 nmol/L, insufficient between 25 and 50 nmol/L and suf-
ficient for level above 50 nmol/L [28].
Statistical analysis
Continuous measurements analyzed were: age (years),
weight (kilograms), height (centimetres), 25-OHD serum
level (nmol/L), calcium and phosphate levels (mmol/L).
Median and interquartile range (IQR) were calculated for
those variables in the study groups. Categorical data were
compared using the Chi-squared test (or Fisher's exact test,
when expected cell sizes were smaller than five). The
Wilcoxon-Mann–Whitney test was used for continuous
measurements to test relationships in unpaired analysis,
when assumed that the dependent variable was a not nor-
mally distributed interval variable. Moreover, the risk factors
for vitamin D deficiency were evaluated using univariate
and multivariate logistic regression. The variables included
in the analysis were: TB infection status (active TB, latent
TB, and control), gender, age, ethnicity at risk for vitamin D
deficiency, immigration, seasonality (categorized ad autumn-
winter and spring-summer). For each factor the relative risk
(RR) and 95% confident intervals (95% CI) were evaluated.
Statistical analysis was performed using the statistical soft-
ware SPSS for Windows, version 12.0. P <0.05 was consid-
ered statistically significant.




Nine hundred and ninety-six children were included in
this study: 15 (1.5%) from Great Ormond Street Hospital,
London, UK; 63 (6.4%) from Evelina London Children’s
Hospital, London, UK; and 918 (92.1%) from Anna Meyer
Children's University Hospital, Florence, Italy. The study
population characteristics are summarized in Table 1.
TB status
Forty-four (4.4%) children met the criteria for active TB.
The most common condition was pulmonary TB (n = 24;
54.5%). Extra-pulmonary TB was in order of frequency:
lymphadenitis (n = 5; 11.4%), pleural-peritoneal (n = 4;
9.1%), skeletal (n = 4; 9.1%), ocular (n = 1; 2.3%), meningeal
(n = 1; 2.3%). Miliary TB was found in 5 patients (11.4%).
The median length of the treatment was 7 months (range
6–12). Quadruple therapy (isoniazid, rifampicin, etham-
butol, pyrazinamide) was used in 36 children, in 4 of those
in association with steroids. In other 8 cases different anti-
TB treatment associations have been used, mostly because
of resistant mycobacteria.
One hundred and thirty-eight (13.9%) children met
the criteria for latent TB. Double therapy (isoniazid and
rifampicin) for 3 months was the commonest combin-
ation used (91.3%, n = 126). The controls enrolled in the
study were 814 (81.7%).
Vitamin D, calcium and phosphate levels in the study
groups
Vitamin D levels in the different study groups are reported
in Table 2 and illustrated in Figure 1. About half (467;
46.9%) of the children tested, independently from the TB
status, resulted to have an insufficient or deficient vitamin
D level. Hypovitaminosis D was found respectively in 354
(43.5%) of controls, 80 (58%) latent TB and 33 (75%) active
TB. The statistical analysis with the Mann–Whitney U test
showed that vitamin D level was significantly lower in case
of latent and active TB compared to controls (p < 0.0001),
with median level respectively of 45 nmol/L (IQR: 30–
62.5), 27.8 nmol/L (IQR: 19–50) and 52.5 nmol/L (IQR:
31.5-67.5).
Vitamin D levels were significantly lower in latent TB
compared to controls (p = 0.002), in active TB compared
to controls (p < 0.0001) and in active TB compared to la-
tent TB (p = 0.001).
Moreover, a deficient vitamin D level was found in
higher percentage in the active TB group (n = 18; 40.9%)
compared to latent TB (n = 28; 20.3%) and controls
(13.9%) (P < 0.0001). An insufficient level of vitamin D
was more frequently found in the latent TB group (n =
113; 37.7%, P < 0.0001) (Figure 2).
All the variable analysed were statistically significant
also according to the US Endocrinology Society vitamin D
status classification (P < 0.0001) (29).
Calcium and phosphate levels (median and IQR) in the
different study groups are reported in Table 2.
In the study population 159 (16%) children were
vitamin D deficient, 308 (30.9%) insufficient and 529
(53.1%) sufficient.
The correlation between vitamin D status and other
factors (age, gender, seasonality, calcium and phosphate
levels) has been reported in Table 3.
Vitamin D level was significantly lower if tested during
Autumn-Winter compared to Spring-Summer (P < 0.0001)
(Figure 3).
Multivariate analysis
A multivariate logistic regression analysis was used to
exclude possible confounding factors. This analysis con-
firmed the risk of vitamin D deficiency to be statistically
correlated with TB infection (RR = 1.61; 95% CI:1.086-
2.388; P = 0.018;), and higher in active TB compared to
latent TB and controls, ( RR = 4.587; 95% CI: 1.190-
9.608; P < 0.0001). In the multivariate analysis the re-
sults were adjusted for the different centres.
There was no significant correlation between hypovitami-
nosis D and gender (P = 0.113; RR = 0.799; 95% CI: 0.605-
1.055), ethnicity at risk of hypovitaminosis D (P = 0.688;
RR = 1.610; 95% CI: 0.715-1.747) and immigration
(P = 0.428; RR = 1.316; 95% CI: 0.668-2.590). On the con-
trary, a correlation between hypovitaminosis D and age
(P < 0.0001; RR = 1.147; 95% CI: 1.105-1.190) and be-
tween vitamin D deficiency and seasonality (P < 0.0001;
RR = 2.208; 95% CI: 2.132-3.698) was found.
Vitamin D supplementation
In case of hypovitaminosis D, different vitamin D sup-
plementation protocols were used in the three centres,
according with the most recent international guidelines
[28-31]. At Anna Meyer Children's University Hospital,
Florence, Italy, 1000 IU of colecalciferol were adminis-
tered daily for 8 weeks. At Evelina London Children’s
Hospital, London, UK, 3,000, 6,000, 10,000 or 20,000 IU
of colecalciferol were used daily for 6 weeks depending
on the severity of hypovitaminosis D. At Great Ormond
Street Hospital, London, UK 50,000 IU of ergocalciferol
were administered daily for 3 to 6 days.
Only one-third (133; 28.5%) of the patients with a low
level of vitamin D received vitamin D supplementation.
Vitamin D supplementation was prescribed in 71 con-
trols, 36 latent TB and 26 active TB, respectively 20%,
45% and 79% of children with hypovitaminosis D in the
3 different groups.
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Table 1 Study population characteristics
Controls n = 814 Latent TB n = 138 Active TB n = 44 Total n = 996 P
Enrolling centre, n (%): <0.0001
- Evelina London Children’s 21 (2.6%) 25 (18.1%) 17 (38.6%) 63 (6.4%)
Hospital, London, UK
- Great Ormond Street 0 (0%) 0 (0%) 15 (34.1%) 15 (1.5%)
Hospital, London, UK
- Anna Meyer Children's University Hospital, Florence, Italy 793 (97.4%) 113 (81.9%) 12 (27.3 %) 918 (92.1%)
Age in years, median (IQR) 5.5 (3.1-8.1) 6.9 (4.3-10.8) 4.7 (3.0-11.6) 5.8 (3.1-8.5) <0.0001
Gender, n (%): <0.0001
- Male 496 (60.9%) 85 (61.6%) 15 (34.1%) 596 (59.4%)
- Female 310 (38.1 %) 52 (37.7%) 29 (65.9 %) 391 (39.6%)
- Not known 8 (1%) 1 (0.7%) 0 (0%) 9 (0.9%)
Country of origin*, n (%): <0.0001
- Asia 146 (17.9%) 19 (13.8%) 4 (9.1%) 169 (17%)
- Latin America 183 (22.5%) 24 (17.4%) 4 (9.1%) 211 (21.2%)
- Eastern Europe§ 269 (33%) 57 (41.3%) 5 (11.4%) 331 (33.2%)
- Western Europe 36 (4.4%) 7 (5.1%) 3 (6.8 %) 46 (4.6%)
- Nord Africa 16 (2%) 1 (0.7%) 2 (4.5%) 19 (1.9%)
- Sub-Saharan Africa 151 (18.6%) 29 (21%) 25 (56.8 %) 205 (20.6%)
- Other 8 (1%) 0 (0%) 0 (0%) 8 (0.8%)
- Not known 5 (0.6%) 1 (0.7%) 1 (2.3%) 7 (0.7%)
Ethnic group, n (%): <0.0001
- African 168 (20.7%) 30 (21.7%) 27 (61.4%) 225 (22.6%)
- Asiatic 146 (17.9%) 19 (13.8%) 4 (9.1%) 169 (17%)
- Caucasian 306 (37.6%) 64 (46.4%) 8 (18.2%) 378 (37.9%)
- Hispanic 183 (22.5%) 24 (17.4%) 4 (9.1%) 211 (21.2%)
- Other 6 (0.7%) 0 (0%) 0 (0%) 6 (0.6%)
- Not known 5 (0.6%) 1 (0.7%) 1 (2.2%) 7 (0.7%)
BCG, n (%): 0.109
- Yes 460 (56.5%) 89 (64.5%) 20 (45.5%) 569 (57.1%)
- No 244 (30.0%) 40 (29.0%) 19 (43.2%) 303 (30.4%)
- Not known 110 (13.5%) 9 (6.5%) 5 (11.4%) 124 (12.4%)
Risk factors for vitamin D 0.932
deficiency†, n (%):
- Yes 470 (57.7%) 74 (53.6%) 32 (72.7%) 576 (57.8%)
- No 344 (42.3%) 64 (46.4%) 12 (27.3%) 420 (42.2%)
Risk factors for TB <0.0001
infection, n (%):
- Tb contact 92 (11.4%) 31 (22.5%) 27 (21.2%) 150 (15.1%)
- Travel to/immigrated from 695 (85.3%) 104 (75.4%) 10 (22.8%) 809 (80.1%)
TB endemic country
- Not known 27 (3.3%) 3 (2.1%) 7 (15.9%) 37 (3.7%)
IGRA, n (%): <0.0001
- Positive 0 (0.0%) 45 (32.6%) 28 (63.6%) 73 (7.3%)
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Discussion
The high prevalence of hypovitaminosis D in children
[32,33] is confirmed in our study, based on a large data
set, reaching 47% of children tested, independently from
their TB status.
The correlation between vitamin D deficiency and TB
disease was previously demonstrated in adults [4-6,8-14],
although some authors do not agree with this hypothesis
[34-40]. No paediatric study with a matched control group
is available in literature, and our study’s aim is to fill this
gap. Three studies on a possible correlation between vita-
min D deficiency and TB in the paediatric population
were previously published [41-43], including overall 442
children. In the first study on refugee children, a vitamin
D level was significantly lower in 92 children with TB
infection compared to 236 healthy controls [41]. The main
limitations of this retrospective study were the omission
of routine IGRA testing in the definition of TB status and
the missing data about BCG vaccination [41]. Hypovitami-
nosis D prevalence in latent and active TB was 86% in a
retrospective study on 64 children [42]. The principal
limitation of this study was the lack of an age and ethnic-
ally matched control group without a history of TB infec-
tion or disease [42]. Finally, in a randomised study, done
on a small number of children (n = 24), vitamin D supple-
mentation (colecalciferol 1000 UI daily for 8 weeks) was
added to TB treatment, leading to clinical and radio-
logical improvement compared to the standard treat-
ment alone [43].
The correlation between low vitamin D and TB disease
is confirmed in our study on a large paediatric popula-
tion including a matched control group. Hypovitamino-
sis D affected up to 75% children with active TB (P <
0.0001). Moreover, the active TB group exhibited the
lowest level of vitamin D. Hypovitaminosis D was four
times more likely in children with active TB compared
to healthy controls. This correlation was confirmed
using a multivariate logistic regression analysis, in order
to exclude possible confounding factors, and the results
were adjusted considering also the different enrolling
centre.
About two-third of the study population ethnicity was
at high risk for vitamin D deficiency (African, Asiatic
and Hispanic). It is well known that the major risk
factors in these populations are dark skin, reduced ex-
posure to sunlight due to long clothing and vegetarian
diet [32]. The ethnical background at risk of hypovitami-
nosis D were homogeneously distributed in the 3 study
groups. Interestingly, in our study hypovitaminosis D oc-
curred also in the Caucasian group, accounting for about
one-third of the cases. Vitamin D was deficient in 32.7%
of Caucasian children and insufficient in 37.3%. More-
over, about 80% of children tested in the UK had hypovi-
taminosis D (respectively 43.6% was vitamin D deficient
and 35.9% insufficient) compared to 44.1% of children
tested in Italy (respectively 13.6% was vitamin D defi-
cient and 30.5% insufficient). This difference could be
mainly explained by lower sun exposure in UK with
Table 1 Study population characteristics (Continued)
- Negative 792 (97.3%) 71 (51.4%) 7 (15.9%) 870 (87.3%)
- Not known 22 (2.7%) 22 (15.9%) 9 (20.5%) 53 (5.3%)
TST, n (%): <0.0001
- Positive 0 (0.0%) 120 (87%) 32 (72.7%) 152 (15.3%)
- Negative 777 (95.5%) 10 (7.2%) 2 (4.5%) 789 (79.2%)
- Not known 37 (4.5%) 8 (5.8%) 10 (22.7%) 55 (55.2%)
*Whether the child’s family is originally from a TB endemic country, this has been indicated as country of origin, independently from the country of birth.
§Albania, Belarus, Bulgaria, Kosovo, Macedonia, Moldavia, Poland, Czech Republic, Romania, Russia, Serbia, Slovakia, Slovenia, Ukraine, Hungary.
†African, Asiatic and Hispanic ethnic group.
Table 2 Vitamin D, calcium and phosphate levels in the different study groups
Controls n = 814 Latent TB n = 138 Active TB n = 44 Total n = 996 P
Vitamin D level, n (%): 0.0001
- Deficient (<25 nmol/L) 113 (13.9%) 28 (20.3%) 18 (40.9%) 159 (16%)
- Insufficient (25–50 noml/L) 241 (29.6%) 52 (37.7%) 15 (34.1%) 308 (30.9%)
- Sufficient (>50 nmol/L) 460 (56.5%) 58 (42%) 11 (25%) 529 (53.1%)
Vitamin D level (nmol/L), median (IQR) 52.5 (31.5-67.5) 45 (30–62.5) 27.8 (19–50) 35 (24–54.5) 0.0001
Calcium (mmol/L), median (IQR) 2.38 (2.3-2.45) 2.38 (2.3-2.42) 2.35 (2.25-2.45) 2.4 (2.26-2.46) 0.709
Phosphate (mmol/L), median (IQR) 1.62 (1.49-1.71) 1.75 (1.32-1.78) 1.42 (1.23-1.6) 1.5 (1.28-1.61) 0.002
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Figure 1 Vitamin D levels (median and IQR) in the different study groups. About half (467; 46.9%) of the children tested, independently
from the TB status, resulted to have an insufficient or deficient vitamin D level. Hypovitaminosis D was found respectively in 354 (43.5%) of
controls, 80 (58%) latent TB and 33 (75%) active TB.
Figure 2 Vitamin D status defined by ESPGHAN according to TB status. A deficient vitamin D level was found in higher percentage in the
active TB group (n = 18; 40.9%) compared to latent TB (n = 28; 20.3%) and controls (13.9%) (P < 0.0001). An insufficient level of vitamin D was
more frequently found in the latent TB group (n = 113; 37.7%, P < 0.0001).
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Table 3 Characteristics of the population according to vitamin D status
Deficient n = 159 Insufficient n = 308 Sufficient n = 529 Total n = 996 P
TB status, n (%): <0.0001
- Controls 113 (71.1%) 241 (78.2%) 460 (87%) 814 (81.7%)
- Latent TB 28 (17.6%) 52 (16.9%) 58 (11%) 138 (13.9%)
- Active TB 18 (11.3%) 15 (4.9%) 11 (2%) 44 (4.4%)
Enrolling centre, n (%): <0.0001
- Evelina London Children’s 26 (16.4%) 23 (7.5%) 14 (2.6%) 63 (6.4%)
Hospital, London, UK
- Great Ormond Street 8 (5%) 5 (1.6%) 2 (0.4%) 15 (1.5%)
Hospital, London, UK
- Anna Meyer Children's University Hospital, Florence, Italy 125 (78.6%) 280 (90.9%) 513 (97%) 918 (92.1%)
Age, median (IQR) 6.5 (4.2-10.3) 6.6 (4–9.7) 4.8 (2.5-7.6) 5.8 (3.1-8.5) <0.0001
Gender, n (%): 0.106
- Male 85 (53.5%) 182 (59.1%) 329 (62.2%) 596 (59.8%)
- Female 74 (46.5%) 122 (39.6%) 195 (36.9%) 391 (39.3%)
- Not known 0 (0%) 4 (1.3%) 5 (0.9%) 9 (0.9%)
Country of origin*, n (%): <0.0001
- Asia 27 (17%) 44 (14.3%) 98 (18.5%) 169 (17%)
- Latin America 25 (15.7%) 74 (24%) 112 (21.2%) 211 (21.2%)
- Eastern Europe § 48 (30.2%) 95 (30.8%) 188 (35.5%) 331 (33.2%)
- Western Europe 4 (2.5%) 18 (5.8%) 24 (4.5%) 46 (4.6%)
- Nord Africa 7 (4.4%) 8 (2.6%) 4 (0.8%) 19 (1.9%)
- Sub-Saharan Africa 42 (26.4%) 65 (21.1%) 98 (18.5%) 205 (20.6%)
- Other 1 (0.6%) 3 (1%) 4 (0.8%) 8 (0.8%)
- Not known 5 (3.1%) 1 (0.3%) 1 (0.2%) 7 (0.7%)
Ethnic group, n (%): <0.0001
- African 50 (30.8%) 74 (24%) 101 (19.1%) 225 (22.6%)
- Asiatic 24 (15.1%) 43 (14%) 102 (19.3%) 169 (17%)
- Caucasian 52 (32.7%) 115 (37.3%) 211 (39.9%) 378 (37.9%)
- Hispanic 27 (17%) 73 (23.7%) 111 (21%) 211 (21.2%)
- Other 1 (1.2%) 2 (0.7%) 3 (0.5%) 6 (0.6%)
- Not known 5 (3.2%) 1 (0.3%) 1 (0.2%) 7 (0.7%)
Risk factors for vitamin D 0.932
deficiency†, n (%):
- Yes 93 (58.5%) 180 (58.4%) 303 (57.3%) 576 (57.8%)
- No 66 (41.5%) 128 (41.6%) 226 (42.7%) 420 (42.2%)
Season when blood test was <0.0001
done, n (%):
- Spring-Summer 58 (36.5%) 145 (47.1) 339 (64.1%) 542 (54.4%)
- Winter-Autumn 101 (63.5%) 163 (52.9) 190 (35.9%) 454 (45.6%)
Vitamin D level (nmol/L), median (IQR) 20 (15.5-22.5) 37.5 (32.5-42.5) 72.5 (57.5-87.5) 35 (24–54.5)
Calcium (mmol/L), median (IQR) 2.35 (2.28-2.42) 2.37 (2.3-2.43) 2.38 (2.33-2.48) 2.4 (2.26-2.46) 0.030
Phosphate (mmol/L), median (IQR) 1.5 (1.3-1.65) 1.59 (1.41-1.68) 1.65 (1.49-1.81) 1.5 (1.28-1.61) 0.001
*Whether the child’s family is originally from a TB endemic country, this has been indicated as country of origin, independently from the country of birth.
§Albania, Belarus, Bulgaria, Kosovo, Macedonia, Moldavia, Poland, Czech Republic, Romania, Russia, Serbia, Slovakia, Slovenia, Ukraine, Hungary.
†African, Asiatic and Hispanic ethnic group.
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respect to Italy and probably also by different diet within
the two countries. However, the high percentage of hypo-
vitaminosis in Italy despite good sun exposure, affecting
about half of the children tested, should increase the
awareness of this problem also in countries known to be
at low risk for vitamin D deficiency.
Hypovitaminosis D was statistically more frequent if
tested during autumn and winter compared to spring
and summer. This seasonality has been well described
and is mainly related to sun exposure [6,12,41,44].
Surprisingly, only one-third of the patients with hypovi-
taminosis D received vitamin D supplementation, with dif-
ferent protocols depending on the prescribing centre. The
protocols used in the three centres were in agreement
with the most recent international guidelines [28-31]. This
data should alert the physicians about the need of vitamin
D supplementation in children with hypovitaminosis, to
prevent rickets and its complications. However no clinical
sign of rickets was reported in our study population. The
choice of vitamin D regimen in the paediatric population
should take count of compliance, especially in young chil-
dren and in TB patients, which already receive a signifi-
cant amount of drugs. The need of clear guidelines for
children with hypovitaminosis D in this setting should be
addressed, in order to unify the management of vitamin D
supplementation in this group of patients.
The major limitations of our study are: the lack of
homogeneity between the study groups, as the majority of
controls were enrolled in the Italian centre. To minimize
the influence of this factor on our results a multivariate
analysis was performed, including the enrolling centre as a
categorical variable. Moreover data regarding parathyroid
hormone, alkaline phosphatase were lacking. In our study
the hypovitaminosis D definition used was in keeping with
ESPGHAN guidelines [28], although we were aware about
different definitions. To avoid this bias we performed the
analysis considering also vitamin D status classification by
the US Endocrine Society [29], and the results didn’t
change substantially.
Conclusions
Our large population study confirms an increasing inci-
dence of hypovitaminosis D in Europe, within native and
immigrated children, and the role played by vitamin D
status in TB disease.
In our study hypovitaminosis D was significantly associ-
ated with TB infection. Further studies are needed to
evaluate a possible role of vitamin D in the treatment and
prevention of tuberculosis in children, especially novel
randomized controlled trials to compare TB treatment
outcomes in children receiving vitamin D supplementa-
tion in addition to the standard therapy.
Figure 3 Vitamin D level according to seasonality. Vitamin D level was significantly lower if tested during Autumn-Winter compared to
Spring-Summer (P < 0.0001).
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